These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 23665271

  • 1. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
    Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, Trabucco S, Di Clemente D, Selvaggi FP, Battaglia M, Ditonno P.
    J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker.
    Qian X, Li C, Pang B, Xue M, Wang J, Zhou J.
    PLoS One; 2012 Dec; 7(5):e37225. PubMed ID: 22615945
    [Abstract] [Full Text] [Related]

  • 4. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [Abstract] [Full Text] [Related]

  • 5. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Jun; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 6. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD.
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D.
    Clin Chim Acta; 2012 Aug 16; 413(15-16):1274-8. PubMed ID: 22542564
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.
    BJU Int; 2013 Aug 16; 112(3):313-21. PubMed ID: 23826841
    [Abstract] [Full Text] [Related]

  • 11. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.
    Urology; 2007 Feb 16; 69(2):320-5. PubMed ID: 17320672
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 16; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 13. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 16; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 14. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G.
    Cancer Biomark; 2013 Aug 16; 13(4):227-34. PubMed ID: 24240583
    [Abstract] [Full Text] [Related]

  • 15. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr 16; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 16. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.
    Clin Cancer Res; 2005 Sep 15; 11(18):6582-8. PubMed ID: 16166436
    [Abstract] [Full Text] [Related]

  • 17. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar 15; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 18. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.
    BJU Int; 2012 Dec 15; 110(11):1661-5. PubMed ID: 22564540
    [Abstract] [Full Text] [Related]

  • 19. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, Randone D, Abdollah F, Capitanio U, Larcher A, Lista G, Gadda GM, Bini V, Montorsi F, Guazzoni G.
    J Urol; 2013 Aug 15; 190(2):496-501. PubMed ID: 23466239
    [Abstract] [Full Text] [Related]

  • 20. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug 15; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.